Biodesix Inc

Thermo Fisher Scientific announced several product and collaboration updates earlier this month, including the cGMP-ready Gibco CHO-K1 Catalog Panel for bioprocessing, a reseller agreement to distribute Evosep's Eno separation platform in proteomics workflows, and expanded involvement in molecular residual disease programs with Biodesix and Memorial Sloan Kettering. Together, the moves deepen Thermo Fisher's role across biologics manufacturing, advanced proteomics, and ctDNA-based cancer monitoring. The Gibco CHO-K1 Catalog Panel sits within Thermo Fisher's biopharma solutions stack alongside offerings such as CTS OpTmizer and CHOvantage cell line tools, and is positioned to support customers from development through manufacturing. Thermo Fisher's narrative projects $54.8 billion revenue and $10.0 billion earnings by 2029, with a $645.15 fair value implying 5% downside to its current price, while some of the lowest ranked analysts assume only about US$54.2 billion of revenue and US$8.7 billion of earnings by 2029. The company said persistent China and tariff risks remain a consideration for investors.

Five biotech stocks profiled by RTTNews reached new 52-week highs last week, with gains ranging from 105% to 235% since their respective publication dates. Twist Bioscience soared 235% to a high of $104.23, driven by strong revenue and an upcoming quarterly report. Biodesix climbed 124% to $23.34 following better-than-expected results, raised guidance, and positive clinical validation data. Mirum Pharmaceuticals rose 133% to $124.44 on consistent revenue growth, the Bluejay Therapeutics acquisition, and positive trial results for Brelovitug and Volixibat. Candel Therapeutics advanced 108% to $9.99 after extended survival data for Aglatimagene and a commercialization agreement with EVERSANA. Indivior Pharmaceuticals gained 105% to $42.81, supported by solid earnings, upbeat guidance, and real-world evidence favoring Sublocade.

Biodesix shares ended the last trading session 10.5% higher at $16.81 on heavy volume. The jump followed Canaccord Genuity raising its price target on the company from $22.00 to $27.00 while maintaining a Buy rating. Biodesix reported strong progress in the first quarter of 2026 across its three objectives of driving top-line growth, improving operational efficiency and leverage, and advancing its pipeline. The company is expected to post a quarterly loss of $0.85 per share, a 46.9% improvement year-over-year, on revenues of $26.1 million, up 30.4% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 4% higher over the last 30 days, and the stock carries a Zacks Rank of 2, or Buy.